Pipeline

New products under development

Auxesis Pharma develops next-generation topical treatments based on research in dermatology, pain control and formulation technology. Loperaderm and Cutivelle are working names for formulations intended to provide pain blocking for more severe wound care as well as removal of certain skin spots. Information about future medicines is published continuously on the website.

Keratosis

Cutivelle™ — (Working name)

Keratoses are very common and benign skin changes, most often appearing from middle age and up and varying in color and shape …

  • Most common benign skin tumor
  • Non-invasive treatment
  • Cosmetic improvement
  • OTC
Under development
Cutivelle™ — (Working name)

About Cutivelle™ — (Working name)

Seborrheic keratosis arises through proliferation of keratinocytes in the epidermis and is strongly age-related with genetic predisposition.

Treatment is usually not medically necessary but may be performed for functional or cosmetic reasons.

?

Ask Auxesis

Digital customer support

Hello! I can help you with common questions about Auxesis Pharma, products, news and shareholder information. What would you like to know?